Ozempic and other GLP-1 medications, widely recognized for their rapid weight-loss effects, may also have unintended consequences on vaginal health, according to gynecologists.
Although Ozempic is FDA-approved solely for managing type 2 diabetes, public demand—and off-label use—has surged due to its significant weight-loss results. Alongside social media posts showcasing dramatic transformations, some users have reported unexpected side effects beyond slimmer physiques.
Among the more surprising revelations are changes to vulvar tissue. One woman who lost 20 kilograms (44 pounds) on Ozempic noted that while other areas of her body avoided loose skin, she experienced a loss of “fat pads” in her vulva.
Her physician reportedly warned that this tissue reduction could cause discomfort while sitting or cycling, suggesting potential corrective options such as fillers or surgery.
Dr. Melanie Bone, consultant OBGYN and U.S. medical director at the gynecological health company Daye, recently addressed how GLP-1 medications may influence vaginal health. In an interview with Newsweek, she highlighted three primary mechanisms:
1. Hormonal Fluctuations
Rapid weight loss can trigger hormonal shifts that affect vaginal lubrication and tissue integrity. Some patients may notice increased dryness as a result, Dr. Bone explained.
2. Dehydration
GLP-1 drugs often reduce appetite and can cause nausea, diarrhea, and vomiting. These effects may contribute to dehydration, which can in turn exacerbate vaginal dryness. Dr. Bone recommends maintaining proper hydration, using vaginal probiotics, and considering vaginal moisturizers if discomfort occurs.
3. Microbiome Disruption
Changes in diet and gut function due to GLP-1 medications may also affect the “gut-vagina axis,” potentially altering discharge, odor, or increasing the risk of infections. Routine screenings and close monitoring are advised to detect any shifts in vaginal health.
Dr. Bone emphasized the importance of open communication with healthcare providers. “Women and AFAB [assigned female at birth] individuals should discuss any vaginal health concerns while using GLP-1 agonists,” she said. “Addressing these effects proactively can improve overall management and health outcomes.”
READ MORE
